TTNP Archives - Page 4 of 4

Developments

Titan Pharma posts double-digit increase in Probuphine shipments

Titan Pharmaceuticals (NASDAQ:TTNP) updated the U.S. commercial relaunch of its Probuphine implant for the treatment for opioid use disorder, reporting that it achieved a double-digit increase in product shipments in...

February 1, 2019

Feature

Titan Pharma relaunch of Probuphine paying early dividends

Titan Pharmaceuticals’ (NASDAQ:TTNP) relaunch of its Probuphine implant for the long-term maintenance treatment of opioid use disorder (OUD) demonstrated promising results with a meaningful increase in product shipments...

January 15, 2019

Executive Moves

Titan Pharma hires commercialization veteran, Dane Hallberg

Titan Pharmaceuticals (NASDAQ:TTNP) appointed Dane Hallberg to the newly created position of EVP and chief commercial officer, effective immediately, with responsibility for leading all of the company’s commercial...

October 2, 2018

Developments

Titan Pharma, Braeburn terminate Probuphine license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) and Braeburn agreed to terminate a December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Under the...

May 30, 2018

Developments

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of...

April 20, 2018

Developments

Molteni acquires Titan Pharma’s European Probuphine IP

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...

March 22, 2018

Feature

Titan’s next ProNeura implant could be game changer in PD

By Len Zehr After gaining widespread attention with its FDA-approved Probuphine implant for the maintenance treatment of opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is setting out to develop an implant to...

October 10, 2017

Feature

Titan’s next ProNeura-based implant dovetails with PD awareness month

By Len Zehr After receiving FDA approval last year for its Probuphine implant as a maintenance treatment for opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is employing its ProNeura drug delivery technology to...

April 25, 2017

Feature

Titan Pharma advancing pipeline in PD, other disorders

By Len Zehr Titan Pharmaceuticals (NASDAQ:TTNP), which is awaiting an FDA approval decision for its six-month Probuphine implant to treat opioid dependence, is advancing its ProNeura implant technology against...

October 13, 2015

Feature

Titan implanting treatments for opioid dependence

By Len Zehr In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick...

August 19, 2014

Tag - TTNP

Titan Pharma posts double-digit increase in Probuphine shipments

Titan Pharma relaunch of Probuphine paying early dividends

Titan Pharma hires commercialization veteran, Dane Hallberg

Titan Pharma, Braeburn terminate Probuphine license agreement

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Molteni acquires Titan Pharma’s European Probuphine IP

Titan’s next ProNeura implant could be game changer in PD

Titan’s next ProNeura-based implant dovetails with PD awareness month

Titan Pharma advancing pipeline in PD, other disorders

Titan implanting treatments for opioid dependence

General

More